Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: A retrospective, cohort study

Drugs and Aging

Volumn 25, Issue 10, 2008, Pages 885-892

  Chapman, Richard H ^a   Petrilla, Allison A ^a   Benner, Joshua S ^a   Schwartz, J Sanford ^b   Tang, Simon S K ^c  

^a IQVIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

Author keywords

Antihyperlipidaemics, therapeutic use; Antihypertensives, therapeutic use; Elderly; Hypertension, treatment; Lipid metabolism disorders, treatment; Patient compliance

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DYSLIPIDEMIA; ELDERLY CARE; FEMALE; FOLLOW UP; HEALTH SERVICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICARE; MEDICATION ADHERENCE; REGISTRIES; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; UNITED STATES;

EID: 52449112363     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825100-00008     Document Type: Article

References (16)

1. WHO. Adherence to long-term therapies: evidence for action [online]. Available from URL: http://www.who.int/entity/chronic_conditions/en/ adherence_report.pdf [Accessed 2006 Mar 27]
2. MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005; 22: 231-55
3. Eaton CB, Feldman HA, Assaf AR, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract 1994; 38: 17-23
4. Asmar R, Vol S, Pannier B, et al. High blood pressure and associated cardiovascular risk factors in France. J Hypertens 2001; 19: 1727-32
5. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006; 98: 204-8
6. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64
7. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23: 528-35
8. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-52
9. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62
10. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61
11. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697-704
12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30
13. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005; Suppl Web Exclusives: W5-152-66
14. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38: 303-12
15. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841-5
16. Wu JYF, Leung WYS, Chang S, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 2006; 333: 522